1048 related articles for article (PubMed ID: 26355382)
1. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
Vaughn JE; Othus M; Powell MA; Gardner KM; Rizzuto DL; Hendrie PC; Becker PS; Pottinger PS; Estey EH; Walter RB
JAMA Oncol; 2015 Nov; 1(8):1120-7. PubMed ID: 26355382
[TBL] [Abstract][Full Text] [Related]
2. Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study.
Walter RB; Lee SJ; Gardner KM; Chai X; Shannon-Dorcy K; Appelbaum FR; Estey EH
Haematologica; 2011 Jun; 96(6):914-7. PubMed ID: 21393334
[TBL] [Abstract][Full Text] [Related]
3. A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia.
Getz KD; Miller TP; Seif AE; Li Y; Huang YS; Bagatell R; Fisher BT; Aplenc R
Cancer Med; 2015 Sep; 4(9):1356-64. PubMed ID: 26105201
[TBL] [Abstract][Full Text] [Related]
4. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.
Fedele PL; Avery S; Patil S; Spencer A; Haas M; Wei A
Intern Med J; 2014 Aug; 44(8):757-63. PubMed ID: 24863325
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations.
Stein EM; Bonifacio G; Latremouille-Viau D; Guerin A; Shi S; Gagnon-Sanschagrin P; Briggs O; Joseph GJ
J Med Econ; 2018 Jun; 21(6):556-563. PubMed ID: 29304724
[TBL] [Abstract][Full Text] [Related]
6. Outpatient supportive care following chemotherapy for acute myeloblastic leukemia.
Allan DS; Buckstein R; Imrie KR
Leuk Lymphoma; 2001 Jul; 42(3):339-46. PubMed ID: 11699398
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
[TBL] [Abstract][Full Text] [Related]
8. Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia.
Gillis S; Dann EJ; Rund D
Am J Hematol; 1996 Jan; 51(1):26-31. PubMed ID: 8571934
[TBL] [Abstract][Full Text] [Related]
9. Outpatient management of acute myeloid leukemia after intensive consolidation chemotherapy is feasible and reduces hospital treatment costs.
Eisele L; Günther F; Ebeling P; Nabring J; Dührsen U; Dürig J
Onkologie; 2010; 33(12):658-64. PubMed ID: 21124036
[TBL] [Abstract][Full Text] [Related]
10. Induction-related cost of patients with acute myeloid leukaemia in France.
Nerich V; Lioure B; Rave M; Recher C; Pigneux A; Witz B; Escoffre-Barbe M; Moles MP; Jourdan E; Cahn JY; Woronoff-Lemsi MC
Int J Clin Pharm; 2011 Apr; 33(2):191-9. PubMed ID: 21744189
[TBL] [Abstract][Full Text] [Related]
11. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Sekeres MA; Maciejewski JP; Erba HP; Afable M; Englehaupt R; Sobecks R; Advani A; Seel S; Chan J; Kalaycio ME
Cancer; 2011 Mar; 117(6):1253-61. PubMed ID: 20960521
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
13. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
14. Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome.
Mabrey FL; Gardner KM; Shannon Dorcy K; Perdue A; Smith HA; Davis AM; Hammer C; Rizzuto D; Jones S; Quach K; Scott BL; Hendrie PC; Percival MM; Walter RB; Appelbaum FR; Estey EH; Becker PS
Blood Adv; 2020 Feb; 4(4):611-616. PubMed ID: 32074276
[TBL] [Abstract][Full Text] [Related]
15. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need.
Goldberg SL; Chen E; Sasane M; Paley C; Guo A; Laouri M
Transfusion; 2012 Oct; 52(10):2131-8. PubMed ID: 22486790
[TBL] [Abstract][Full Text] [Related]
16. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
17. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
Scappaticci GB; Marini BL; Nachar VR; Uebel JR; Vulaj V; Crouch A; Bixby DL; Talpaz M; Perissinotti AJ
Ann Hematol; 2018 Apr; 97(4):573-584. PubMed ID: 29288428
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes.
Trofe-Clark J; Reese PP; Patel HJ; Jakobowski D; Goral S; Doll SL; Abt PL; Bloom RD
Transplantation; 2012 Sep; 94(5):506-12. PubMed ID: 22895613
[TBL] [Abstract][Full Text] [Related]
20. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
Mattiuzzi GN; Kantarjian H; O'Brien S; Kontoyiannis DP; Giles F; Zhou X; Lim J; Bekele BN; Faderl S; Cortes J; Pierce S; Leitz GJ; Raad I; Estey E
Cancer; 2004 Feb; 100(3):568-73. PubMed ID: 14745874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
